Global cancer statistics
| [0005]
|
Science
| [0006]
|
Cancer Res
| [0006]
|
CHEMICAL ABSTRACTS
| [0007]
|
Science
| [0007]
|
Science
| [0007]
|
New Engl. J. Med.
| [0007]
|
Mol Cell Biol
| [0007]
|
Cancer Immunol Immunother
| [0007]
|
Cancer Res.
| [0007]
|
Cancer Immunol Immunother
| [0007]
|
Proc. Annual Meeting Am Assoc Cancer Res
| [0007]
|
Proc Am Assoc Cancer Res
| [0007]
|
Seminars in Oncology
| [0007]
|
Nature Reviews: Molecular Cell Biology
| [0007]
|
J. Clin. Oncol.
| [0008]
|
N Engl J Med
| [0008]
|
J Clin Oncol
| [0008]
|
J Clin Oncol
| [0008]
|
T N Engl J Med
| [0008]
|
N Engl J Med
| [0008]
|
Breast Cancer Res Treat
| [0008]
|
Cancer Treat. Rev.
| [0010]
|
Cancer Treat Rep
| [0010]
|
Science
| [0010]
|
Chem Pharm Bull
| [0010]
|
Maytansine. Cancer Treat Rev
| [0010]
|
J. Clin. Oncol.
| [0012]
|
Cancer
| [0012]
|
Krop
| [0013]
|
New England Journal of Medicine
| [0013]
|
Oncogene
| [0015]
|
Nat Rev Mol Cell Biol
| [0015]
|
Nat Struct Biol
| [0015]
|
Nature
| [0015]
|
Pro Am Soc Cancer Res
| [0015]
|
Cancer Cell
| [0016]
|
Pro Am Soc Clin Oncol
| [0017]
|
Pro Am Soc Clin Oncol
| [0017]
|
J Clin Oncol, 2007 ASCO Annual Meeting Proceedings
| [0018]
|
J Clin Oncol, 2007 ASCO Annual Meeting Proceedings
| [0018]
|
J Clin Oncol 2007 ASCO Annual Meeting Proceedings
| [0019]
|
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine
| [0023]
|
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
| [0023]
|
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2 positive, node--negative tumors 1cm or smaller
| [0023]
|
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
| [0024]
|
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
| [0025]
|
Adjuvant Trastuzumab in HER2-positive breast cancer
| [0026]
|
Preoperative therapy with Trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study
| [0027]
|
Significantly higher pathologic complete remission rate after neoadjuvant therapy with Trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
| [0027]
|
Neoadjuvant chemotherapy with Trastuzumab followed by adjuvant Trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
| [0027]
|
Neoadjuvant treatment with Trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
| [0027]
|
Pathologic complete response after neoadjuvant chemotherapy plus Trastuzumab predicts favorable survival in human epidermal growth factor receptor-2-overexpressing breast cancer : results from the TECHNO trial of the AGO and GBG study groups
| [0027]
|
HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trials
| [0027]
|
Long-term follow-up of HER2-overexpressing Stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy
| [0030]
|
Efficacy of neoadjuvant therapy with Trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer
| [0030]
|
J. Natl. Cancer Inst.
| [0032]
|
J. Natl. Cancer Inst.
| [0032]
|
Successful quality assurance program for HER2 testing in the NSABP Trial for Herceptin
| [0032]
|
J. Natl. Cancer Inst.
| [0032]
|
Proceedings of the American Society of Clinical Oncology Thirty-Eighth Annual Meeting
| [0032]
|
Trialists' Group
| [0032]
|
26th Annual San Antonio Breast Cancer Symposium (SABCS)
| [0032]
|
Proc. ASCO
| [0032]
|
Antibodies, A Laboratory Manual
| [0058]
[0058]
|
Cancer Cell
| [0058]
|
CHEMICAL ABSTRACTS
| [0058]
|
CHEMICAL ABSTRACTS
| [0058]
|
CHEMICAL ABSTRACTS
| [0058]
|
CHEMICAL ABSTRACTS
| [0058]
|
CHEMICAL ABSTRACTS
| [0058]
|
Angew Chem. Intl. Ed. Engl.
| [0058]
|
CHEMICAL ABSTRACTS
| [0059]
|
Remington's Pharmaceutical Sciences
| [0070]
[0074]
|
Pharmaceutical Dosage Forms
| [0074]
|
Remington's Pharmaceutical Sciences
| [0075]
|
Interpreting the significance of changes in health-related quality-of-life scores
| [0133]
|